Ohara Pharmaceutical
VC Fund
Koka, Japan
Ohara Pharmaceutical is a VC fund in Koka focused on Medical and Health Care. Ohara Pharmaceuticals is a pharmaceutical business involved in the development, manufacture, and distribution of pharmaceutical products.
- Total investments:
- 12
- Last investment:
- Lead investor:
- 8%
Last updated:
For AI agents: llms.txt
Industries Ohara Pharmaceutical invests in
MedicalHealth CareBiotechnologySoftwareManufacturing
Stages Ohara Pharmaceutical invests in
Venture - Series UnknownSeries ASeries BSeries DDebt Financing
Countries Ohara Pharmaceutical invests in
JapanKenyaNigeriaMauritius
Round sizes
Series A $2.4M–$10MSeries B $12M–$30MVenture - Series Unknown $1.6M–$20M
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $2.4M–$10M
- Series B
- $12M–$30M
- Venture - Series Unknown
- $1.6M–$20M
Investment Focus
Industry
- Medical 6 (50%)
- Health Care 4 (33%)
- Biotechnology 4 (33%)
- Software 2 (17%)
- Manufacturing 2 (17%)
Stage
- Venture - Series Unknown 5 (42%)
- Series A 3 (25%)
- Series B 2 (17%)
- Series D 1 (8%)
- Debt Financing 1 (8%)
Country
- Japan 5 (42%)
- Kenya 2 (17%)
- Nigeria 1 (8%)
- Mauritius 1 (8%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Seiji Ohara
President and CEO
|
President and CEO | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| MYDAWA is a new and innovative service that allows anyone buy wide range of high quality medication and wellness products affordably and conveniently from your mobile phone. | Venture - Series Unknown / Apr 30, 2025 | ||
| Africa Healthcare Network (“AHN”) has established the first dialysis chain across Sub-Saharan Africa, providing high-quality, life-saving dialysis at affordable cost. AHN brings world-class technical expertise combined with developing world practical operating experience to a region in dire need of quality dialysis treatment. Dialysis is alife-saving treatment for patients with Acute Kidney Injury (AKI) and End-Stage Renal Disease (ESRD). The few hospitals that provide treatment operate centers that are slowly deteriorating while charging prohibitive prices. Additionally, the lack of trained professionals and limited capital investment in care for non-communicable diseases in Sub-Saharan Africa, dialysis centers are few and far between, causing patients to endure the high costs for travel to receive care. Those who cannot afford the costs of treatment and travel are resigned to death. Chronic Kidney Disease (CKD) and AKI are on the rise in the region due to strong epidemiologic factors, including increased urbanization leading to lifestyle diseases, other non-communicable diseases, HIV and other infections and toxins. Utilizing our network of executives/partners, we will secure high-quality equipment and train professionals to provide superior care. Our ability to source lowest cost consumables, operational efficiency and scale, will allow us to lower the cost to patients. The net result is increased access, higher quality and lower cost to patients, while maintaining profitability.AHN operates in Rwanda, Tanzania and Kenya. | Debt Financing / Nov 22, 2023 | ||
| Africa Healthcare Network (“AHN”) has established the first dialysis chain across Sub-Saharan Africa, providing high-quality, life-saving dialysis at affordable cost. AHN brings world-class technical expertise combined with developing world practical operating experience to a region in dire need of quality dialysis treatment. Dialysis is alife-saving treatment for patients with Acute Kidney Injury (AKI) and End-Stage Renal Disease (ESRD). The few hospitals that provide treatment operate centers that are slowly deteriorating while charging prohibitive prices. Additionally, the lack of trained professionals and limited capital investment in care for non-communicable diseases in Sub-Saharan Africa, dialysis centers are few and far between, causing patients to endure the high costs for travel to receive care. Those who cannot afford the costs of treatment and travel are resigned to death. Chronic Kidney Disease (CKD) and AKI are on the rise in the region due to strong epidemiologic factors, including increased urbanization leading to lifestyle diseases, other non-communicable diseases, HIV and other infections and toxins. Utilizing our network of executives/partners, we will secure high-quality equipment and train professionals to provide superior care. Our ability to source lowest cost consumables, operational efficiency and scale, will allow us to lower the cost to patients. The net result is increased access, higher quality and lower cost to patients, while maintaining profitability.AHN operates in Rwanda, Tanzania and Kenya. | $20M / Venture - Series Unknown / Nov 22, 2023 | ||
| Helium Health is taking hospitals and clinics digital in Africa with a suite of software tools. It specializing in developing hospital software to manage patients’ health records and data. It helps hospitals digitize medical records, manage operations, and apply for financing; while providing a telemedicine solution to doctors. Using tech to builda modern and affordable healthcare system, Helium aims to be the largest healthcare data exchange in Africa.The company was founded in 2016 and is based in Lagos, Nigeria. | $30M / Series B / Jun 05, 2023 | ||
| Revital Healthcare is a manufacturer of medical devices and disposables for hospitals and other medical laboratories. It offers single-use syringes, needles, re-use prevention syringes and auto-disable syringes which helps in reducing the transmission of HIV and other blood-borne diseases along with infusion sets, blood transfusion sets and bloodcollection tubesThe company was established in 2006 and is headquartered in Kilifi, Kenya. | $3M / Venture - Series Unknown / Dec 21, 2021 | ||
| HACARUS is a provider of Explainable Lightweight AI Tools, backed by Miyako Capital (Kyoto University) among others. Its solutions are used in the Medical and Manufacturing fields to enable humans to make better, faster and more reliable decisions, based on AI driven insights. Hacarus' proprietary AI engine is built using Sparse Modeling, anAI method that understands data like a human would - by its unique key features and is far more resource, time and energy efficient when compared to Deep Learning. | $12.4M / Series B / Nov 16, 2020 | ||
| J-Pharma’s mission is to help mankind by creating and developing novel pharmaceuticals based upon a human-genomic approach; an approach where people with specific diseases are treated with novel and selective agents. J-Pharma’s intellectual property (IP) embraces the notion that cell membrane transporters are tightly associated to many diseases. Inaddition to drug molecules that target specific transporters, J-Pharma has discovered several important drug transporters within the human body that may be used to evaluate and optimize pharmacokinetics of new drug candidates. We believe that J-Pharma’s pipelines will lead to new agents and processes (i.e. diagnostic methods) and will increase the quality of life for an ageing population in industrialized countries. J-Pharma’s overall goal is to contribute globally to the maintenance of human health and improve human welfare through the creation of new drugs. | $16.7M / Series D / Jul 30, 2020 | ||
| Helium Health is taking hospitals and clinics digital in Africa with a suite of software tools. It specializing in developing hospital software to manage patients’ health records and data. It helps hospitals digitize medical records, manage operations, and apply for financing; while providing a telemedicine solution to doctors. Using tech to builda modern and affordable healthcare system, Helium aims to be the largest healthcare data exchange in Africa.The company was founded in 2016 and is based in Lagos, Nigeria. | $10M / Series A / Apr 30, 2020 | ||
| PRISM provider of a therapeutic treatment for non-oncology indications.The company develops therapeutic agents that are used to cure pulmonary fibrosis, cancer and incurable diseases. | $1.8M / Venture - Series Unknown / Apr 01, 2019 | ||
| HekaBio is a healthcare development, investment, and commercialization platform with experience in oncology, radiation, and cardiovascular therapies. They invest in innovations in oncology, radiation, and cardiovascular therapy and commercialization. HekaBio enables patients by accelerating access to global healthcare innovations. | $4.9M / Series A / Dec 07, 2018 | ||
| See all 12 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
SaaS Investors
112,472 investors
Software Investors
55,440 investors
Health Care Investors
47,147 investors
Climate Investors
43,790 investors
Manufacturing Investors
26,762 investors
Biotech Investors
23,541 investors
Biotechnology Investors
20,889 investors
Medical Investors
20,530 investors
SaaS VC Funds
69,112 investors
FAQ
What does Ohara Pharmaceutical invest in?
Ohara Pharmaceutical invests primarily in Medical, Health Care and Biotechnology startups, most often at Venture - Series Unknown and Series A stage. Most of the 12 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Ohara Pharmaceutical's check size?
Ohara Pharmaceutical typically joins rounds of $2.4M–$10M at Series A, $12M–$30M at Series B and $1.6M–$20M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Ohara Pharmaceutical participates in.
How do I contact Ohara Pharmaceutical?
Public channels for Ohara Pharmaceutical include LinkedIn, the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Ohara Pharmaceutical?
The team at Ohara Pharmaceutical includes Seiji Ohara (President and CEO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
